Who is sponsoring NCT05379036?

NCT05379036 is sponsored by I.M. Sechenov First Moscow State Medical University.

What drugs are being tested in NCT05379036?

Interventions in NCT05379036: prescribing anapproved drug, examination.

What condition does NCT05379036 study?

NCT05379036 studies Irritable Bowel Syndrome With Diarrhea.

Is NCT05379036 still recruiting?

NCT05379036 is currently status unknown. Last updated 18 May 2022.

Last reviewed 2022-05-18 · How we verify

NCT05379036

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intestinal Permeability and Intestinal Microbiota in Irritable Bowel Syndrome

Status unknown Phase 4 Last updated 18 May 2022

What this trial tests

Phase 4 trial testing prescribing anapproved drug, examination in Irritable Bowel Syndrome With Diarrhea in 60 participants. Status unknown.

Timeline

23 June 2021

Primary endpoint
31 May 2022

31 May 2022

Quick facts

Lead sponsor	I.M. Sechenov First Moscow State Medical University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	60
Start date	23 June 2021
Primary completion	31 May 2022
Estimated completion	31 May 2022
Sites	1 location across Russia

Drugs / interventions tested

prescribing anapproved drug, examination — full drug profile →

Conditions studied

Irritable Bowel Syndrome With Diarrhea — all drugs for Irritable Bowel Syndrome With Diarrhea →

Sponsor

I.M. Sechenov First Moscow State Medical University

Who can join

Adults 18 to 59, any sex, with Irritable Bowel Syndrome With Diarrhea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with diarrhea-predominant irritable bowel syndrome (IBS) and functional dyspepsia (FD) were examined and received treatment in the study. Severity of complaints and quality of life patients were assessed according to questionnaires. The state of the intestinal barrier (analysis of the protein composition, intestinal mucin levels in biopsies, serum zonulin level in blood), the composition of the gut microbiota (16S rRNA gene sequencing), bacterial metabolic function (short-chain fatty acid levels in feces), and the presence of gut inflammation (levels of lymphocytes and eosinophils in biopsies) were assessed in the patients. Patients were divided into 3 treatment groups: trimebutin + placebo, rebamipide + placebo, trimebutin + rebamipide. The above parameters were compared in patients before and after treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of Rebamipide on the Intestinal Barrier, Gut Microbiota Structure and Function, and Symptom Severity Associated with Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Randomized Controlled Trial.
Kovaleva A, Poluektova E, Maslennikov R, Karchevskaya A, et al · · 2023 · cited 3× · PMID 37763004 · DOI 10.3390/jcm12186064

Verify or expand the search:

Other I.M. Sechenov First Moscow State Medical University trials

Trials by the same sponsor.

NCT07348991 — Predicting Severe Cardiac Arrhythmias in the Perioperative Period Using AI-ECG · not yet recruiting
NCT07412457 — Guideline Adherence in Dyslipidemia With Clinical Decision Support · not yet recruiting
NCT07396792 — Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram · not yet recruiting
NCT07412418 — Screening for Pulmonary Embolism Using Single-channel Electrocardiogram · not yet recruiting
NCT07518550 — Maternal and Fetal Electrocardiograms Separation Algorithm · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05379036 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by I.M. Sechenov First Moscow State Medical University
Last refreshed: 18 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05379036.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing